Everything below concerns LC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-16. Numbers and descriptions here follow the published literature rather than marketing material.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or flake |
| Solubility class | Soluble in water and aqueous buffer | Also soluble in some polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Typical analytical method | LC-MS/MS | Reversed-phase separation with mass detection |
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
=== Pulmonary function test === The forced vital capacity may be monitored at intervals to detect increasing muscular weakness. Acutely, negative inspiratory force may be used to determine adequacy of ventilation; it is performed on those individuals with MG.
== Further reading == "Biographical Entry: Dr. Martin Litchfield West"[link removed], Debrett's People of Today, Debrett's Limited, 18–20 Hill Rise, Richmond, Surrey TW10 6UA United Kingdom. Fries, Almut (2015). "Martin Litchfield West (1937–2015)". Studia Metrica et Poetica. 2 (2): 152–158. doi:10.12697/smp.2015.2.2.12. ISSN 2346-6901. Lightfoot, J. L. (September 2017). "Martin Litchfield West" (PDF). Proceedings of the American Philosophical Society. 161 (3): 285–292.
=== Cancer === In 2007 reports emerged in the press and via the Internet that Evangelos Michelakis and coworkers at the University of Alberta had reported that sodium dichloroacetate reduced tumors in rats and killed cancer cells in vitro. Because the drug cannot be patented, financing the broad and expensive testing required to obtain FDA approval is problematic. The US Food and Drug Administration enforces the law that prohibits the sale of substances with the suggestion that they are cancer treatments unless they have been approved by the FDA. The American Cancer Society in 2012 stated that "available evidence does not support the use of DCA for cancer treatment at this time." Physicians warned of potential problems if people attempt to try DCA outside a controlled clinical trial. One problem with attempting this is obtaining the chemical. One fraudster was sentenced to 33 months in prison for selling a white powder containing starch, but no DCA, to people with cancer. The only monitored in vivo dosage of five human patients with glioblastoma with DCA was not designed to test its efficacy against their cancer. This study was rather to see whether it could be given at a specific dosage safely without causing side effects (e.g. neuropathy). All five patients were receiving other treatments during the study.
Amphetamine was first synthesized in 1887 in Germany by Romanian chemist Lazăr Edeleanu who named it phenylisopropylamine; its stimulant effects remained unknown until 1927, when it was independently resynthesized by Gordon Alles and reported to have sympathomimetic properties. Amphetamine had no medical use until late 1933, when Smith, Kline and French began selling it as an inhaler under the brand name Benzedrine as a decongestant. Benzedrine sulfate was introduced 3 years later and was used to treat a wide variety of medical conditions, including narcolepsy, obesity, low blood pressure, low libido, and chronic pain, among others. During World War II, amphetamine and methamphetamine were used extensively by both the Allied and Axis forces for their stimulant and performance-enhancing effects. As the addictive properties of the drug became known, governments began to place strict controls on the sale of amphetamine. For example, during the early 1970s in the United States, amphetamine became a schedule II controlled substance under the Controlled Substances Act. In spite of strict government controls, amphetamine has been used legally or illicitly by people from a variety of backgrounds, including authors, musicians, mathematicians, and athletes. Amphetamine is illegally synthesized in clandestine labs and sold on the black market, primarily in European countries. Among European Union (EU) member states in 2018, 11.9 million adults of ages 15–64 have used amphetamine or methamphetamine at least once in their lives and 1.7 million have used either in the last year.
Sources: en.wikipedia.org
== Elastosis == Elastosis is the buildup of elastic fibers in tissues, and is a form of degenerative disease. There are a multitude of causes, but the most commons cause is actinic elastosis of the skin, also known as solar elastosis, which is caused by prolonged and excessive sun exposure, a process known as photoaging. Uncommon causes of skin elastosis include elastosis perforans serpiginosa, perforating calcific elastosis and linear focal elastosis.
Nefazodone, sold formerly under the brand names Serzone, Dutonin, and Nefadar among others, is an atypical antidepressant medication which is used in the treatment of depression and for other uses. Nefazodone was withdrawn in most countries by 2004 due to liver toxicity. In December 2021, it was published that despite shortage it is still available in the United States. As of February 2026 it is available in the United States in generic form. The medication is taken by mouth. Side effects of nefazodone include dry mouth, sleepiness, nausea, dizziness, blurred vision, weakness, lightheadedness, confusion, and postural low blood pressure, among others. Rarely, nefazodone can cause serious liver damage, with an incidence of death or liver transplantation of about 1 in every 250,000 to 300,000 patient years. Nefazodone is a phenylpiperazine compound and is related to trazodone. It has been described as a serotonin antagonist and reuptake inhibitor (SARI) due to its combined actions as a potent antagonist of the serotonin 5-HT2A and 5-HT2C receptors and weak serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). Nefazodone was introduced for medical use in 1994. Generic versions were introduced in 2003. Serious liver toxicity was first reported with nefazodone in 1998, and it was withdrawn from most markets by 2004. However, as of 2023, it continues to be available in the United States in generic from one manufacturer, Teva Pharmaceuticals and is manufactured in Israel.
This use a treatment for disease was pioneered in 1890 by Emil von Behring and Shibasaburo Kitasato, who first demonstrated that the endotoxin from the infectious diseases diphtheria and tetanus could be used to prevent or cure non-immunized animals using serum transfusions from an immune animal to a susceptible one. Building on in this logic, and at the same session of the Society of Biology in Paris on February 10, 1894, Albert Calmette at the Pasteur Institute and independently Césaire Phisalix and Gabriel Bertrand at the Department of Pathology and Chemistry in the National Museum of National History in France, announced that they had achieved treatment of a vulnerable animal with serum from an immunized one both using snake venom. Calmette went on subsequently to immunize horses using venom from Indian cobras, and the resulting Serum Antivenimeux (antivenomous serum) became the first commercially available antivenom product. In 1895 Sir Thomas Fraser, Professor of Medicine at the University of Edinburgh, also produced a serum to act against cobra venom. His "antivenene" was effective in the laboratory. In 1901, Vital Brazil, working at the Instituto Butantan in São Paulo, Brazil, developed the first monovalent and polyvalent antivenoms for Central and South American Crotalus and Bothrops snakes, as well as for certain species of venomous spiders, scorpions, and frogs. In Mexico in 1905, Daniel Vergara Lope developed an antivenom against scorpion venom, by immunizing dogs. In Australia, the Commonwealth Serum Laboratories (CSL) began antivenom research in the 1920s.
Sources: en.wikipedia.org
An alveolar macrophage, pulmonary macrophage, (or dust cell, or dust eater) is a type of macrophage, a professional phagocyte, found in the airways and at the level of the alveoli in the lungs, but separated from their walls. Activity of the alveolar macrophage is relatively high, because they are located at one of the major boundaries between the body and the outside world. They are responsible for removing particles such as dust or microorganisms from the respiratory surfaces. Alveolar macrophages are frequently seen to contain granules of exogenous material such as particulate carbon that they have picked up from respiratory surfaces. Such black granules may be especially common in smoker's lungs or long-term city dwellers. The alveolar macrophage is the third cell type in the alveolus; the others are the type I and type II pneumocytes.
==== Chemical shielding ==== It might appear from the above that all nuclei of the same nuclide (and hence the same γ) would resonate at exactly the same frequency but this is not the case. The most important perturbation of the NMR frequency for applications of NMR is the "shielding" effect of the shells of electrons surrounding the nucleus. Electrons, similar to the nucleus, are also charged and rotate with a spin to produce a magnetic field opposite to the applied magnetic field. In general, this electronic shielding reduces the magnetic field at the nucleus (which is what determines the NMR frequency). As a result, the frequency required to achieve resonance is also reduced. This shift in the NMR frequency due to the electronic molecular orbital coupling to the external magnetic field is called chemical shift, and it explains why NMR is able to probe the chemical structure of molecules, which depends on the electron density distribution in the corresponding molecular orbitals. If a nucleus in a specific chemical group is shielded to a higher degree by a higher electron density of its surrounding molecular orbitals, then its NMR frequency will be shifted "upfield" (that is, a lower chemical shift), whereas if it is less shielded by such surrounding electron density, then its NMR frequency will be shifted "downfield" (that is, a higher chemical shift). Unless the local symmetry of such molecular orbitals is very high (leading to "isotropic" shift), the shielding effect will depend on the orientation of the molecule with respect to the external field (B0).
In analogy to other aziridines, N-methylaziridine can be obtained by a Wenker synthesis from N-methylaminoethanol. This is done either via the sulfuric acid ester or after replacement of the hydroxy group by a chlorine atom (for example by thionyl chloride or chlorosulfuric acid) to N-methyl-2-chloroethylamine and then by using a strong base (cleavage of HCl) in an intramolecular nucleophilic substitution:
=== Cultural outlook === Irish society during this period was extremely Roman Catholic, with Roman Catholic thinkers promoting anti-capitalist, anti-communist, anti-Protestant, anti-Masonic, and antisemitic views in Irish society. Through the works of priests such as Edward Cahill, Richard Devane, and Denis Fahey, Irish society saw capitalism, individualism, communism, private banking, the promotion of alcohol, contraceptives, divorce, and abortion as the pursuits of the old 'Protestant-elite' and Jews, with their efforts combined through the Freemasons. Denis Fahey described Ireland as "the third most Masonic country in the world" and saw this alleged order as contrary to the creation of an independent Irish State.
Sources: en.wikipedia.org
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.
No. Lyophilisation slows degradation rather than stopping it, and the rate depends on residual moisture, temperature and light exposure. Freezer storage extends useful life but does not make the material permanent.
A certificate is only as good as its traceability to a specific batch and a named laboratory. Documents lacking batch numbers, method descriptions or laboratory identifiers carry little weight. Confirming what was actually received generally requires a separate test of the material in hand.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.